Scinai Immunotherapeutics Ltd. American Depositary Shares (SCNI) — Analysis Summary
Scinai Immunotherapeutics Ltd. American Depositary Shares (SCNI) has a market cap of $1.70M with year-over-year revenue growth of +99.2%. Net margin stands at -633.6%. The stock trades at a P/E ratio of -0.2.
Key Takeaways
- Revenue changed +99.2% year-over-year
- Net margin of -633.6%
- P/E ratio of -0.2
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, SCNI posted revenue growth of +99.2% and trades at a P/E of -0.2.
Scinai Immunotherapeutics Ltd. American Depositary Shares (SCNI)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Gross margin at -202.3% — product costs significantly exceed revenue
Operating margin at -575.3% — severe operating losses
Net margin at -633.6% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
45
Headquarters
JERUSALEM, L3
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.